To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the SOW as well as other rapidly emerging viruses that utilize the same…
Ended Awarded Last action
- Contract number
- 75N93022F00001
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $498,500
Award facts
- Opportunity
-
- B12 Solicitation number
- Contract value 81% obligated
-
- $498,500.00 Current, with exercised options
- $616,373.16 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to the University of Alabama at Birmingham (UAB), an internationally renowned research university and academic medical center. The contract, valued at $616,373.16, is a Firm Fixed Price Delivery Order under the "In Vitro Assessments of Antimicrobial Activity (IVAAA)" master IDIQ contract. The objective is to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the Statement of Work, as well as other rapidly emerging viruses using the same assay methodology. This contract does not have a set-aside designation and is expected to be completed by August 28, 2023. UAB has an extensive track record of delivering biomedical and public health research under federal grants and contracts, leveraging its expertise in areas such as cancer, infectious diseases, chronic illnesses, neuroscience, and health disparities.
Description
To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the SOW as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93022F00001?
75N93022F00001 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 29, 2022.
How much is contract 75N93022F00001 worth?
The government has obligated $498,500 on 75N93022F00001. Its potential value, with all options, is $616,373.
Is contract 75N93022F00001 an order under another contract?
Yes. 75N93022F00001 is a delivery order under 75N93019D00016, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93022F00001 competed?
The extent of competition for 75N93022F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award